With the same focus, #SpecializedDiagnostics, Werfen and Omixon are the perfect match. The Omixon team is excited to join Werfen and contribute to #PoweringPatientCare.

Contact us: info@werfen.com | Visit Werfen.com

Products
About Us
Blog
Omixon Academy
Resources
Contact us
Search

Request HLA Assay
MyOmixon

Home ›

Documentation

NanoTYPE™ IFU CE Rev2 (Romanian)

News
Events

NanoTYPE™ IFU CE Rev2 (Romanian)

30/09/2024

Post navigation

← NanoTYPE™ 24/11 CE and NanoTYPER™ Known Product Limitations (Romanian) – v2

NanoTYPE™ IFU CE Rev2 (Czech) →

Werfen acquires Omixon

NANOTYPE EU-IVDR

NEW! HOLOGRAFT ONE

Omixon Blog

Werfen acquires Omixon

16/10/2024

Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation...

more

Events

EVENTS 2024

TESTIMONIALS

Testimonials

The NanoTYPE HLA typing assay is optimally designed and supported by a clear protocol so that the workflow can be easily integrated into any H&I laboratory to be used in daily routine. Dr.Monica Dutescu, MD, PhD, National HLA Laboratory, National Blood Transfusion Institute "Prof.Dr. C.T. Nicolau"
“Once again, I congratulate the new version 4.2 of the Twin which is much faster and optimized in processing time and alignment." Romulo Vianna, PhD Rio de Janeiro, State University |UERJ
"It's astonishing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single-end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
"The Holotype HLA method is optimally designed for the service laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company that works with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
“Omixon has developed an excellent direct genotyping method from next-generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
“NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy-to-use analytical methods and software tools that aid the generation of accurate results are critical for the success of this groundbreaking new technology.”Dr. Lajos Pusztai, Professor at the University of Texas MD
Anderson Cancer Center
“Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek
"Omixon's Holotype HLA provided greater accuracy with fewer ambiguities, particularly for problematic specimens, than our Sanger SBT procedures."Dr. Pamela Kimball, VCU Health System Authority
"The NGS kit for HLA genotyping, unlike others available in the market, provides complete control of the reactions from the beginning to the end of the technical process, thus providing a higher cost-benefit ratio for the Laboratory. HLA TWIN is the best and most complete HLA genotyping program on the market and has helped us solve many problems in our laboratory routine."Dr. Rafael Cita, Fundação Pio XII Barretos
"Due to the higher throughput and resolution compared to Sanger sequencing, NGS technology improved significantly HLA typing. Omixon`s Holotype HLA workflow and HLA Twin software could be easily implemented in H&I laboratories. Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT but also in organ transplantation."Dr. Milena Ivanova, Bulgarian Bone Marrow Registry

Omixon Academy

Improve your knowledge!

Our Training Series provide ABHI accredited webinars, workshops, onsite trainings and online demo.

Contact Us

Just ask! Get answers!

Your questions and comments are important to us. We’ve got you covered.

Omixon Newsletter

Subscribe now!

Leave this field empty if you're human:

By clicking 'Ok' I accept the
Privacy Policy

Sitemap

Products

NanoTYPE™
Holotype HLA™
HLA Twin™
HoloGRAFT™
Training and Field Support

Company

About
Board of Directors
Scientific Advisory Board
Careers / Internships
MyOmixon
Cooperations and Sponsorships
Events

Omixon Academy

HLA Twin Videos
Lab Train Me Videos
Posters
Workshops
Symposiums
Webinars
Accreditation

Contact us

Distributors and Agents

Our Mailing Address:

Omixon Biocomputing Ltd.
H-1117 Budapest,
Kaposvár u. 14-18.,
Hungary, EU

US Branch Office:

Omixon Inc.
6 Liberty Square # 2823
Boston, MA 02109
United States

sales@omixon.com | www.omixon.com

support@omixon.com